Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
December 16, 2024 08:00 ET
|
Senti Biosciences, Inc.
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN...
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
January 05, 2024 16:05 ET
|
Senti Biosciences, Inc.
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024...